Janine Erler

CEO

Professor Janine Erler joined NEUmiRNA in 2022 and has over 22 years’ research experience with a strong focus on translation and innovation in the field of metastasis.

Her lifetime goal has always been to reduce the suffering of patients and she focused her research on directly addressing clinical issues.

Janine was awarded a BSc (Hons, first class) in Molecular Genetics from the University of Sussex in 2000, followed by a PhD in Molecular Pharmacology from the University of Manchester in 2003. She undertook her postdoctoral training at Stanford University studying metastasis 2004-2008. Her most recent training was with INSEAD Business School in Paris in 2018.

Her postdoctoral research resulted in Janine Erler filing a patent and the launch of a start-up that was sold to Gilead Sciences in 2010 for $220 million. Janine Erler says: “This led me to establish two of my own start-ups. I also launched  a precision medicine program with funding from the Innovation Fund Denmark, which ran for five years and has now been expanded with funding from the Novo Nordisk Foundation and the Danish Cancer Society.”

Janine Erler is a fully tenured Professor at the University of Copenhagen, where she leads the Erler Lab, a research group at the Biotech Research and Innovation Centre (BRIC).

Janine Erler joined NEUmiRNA in August 2022 as CEO, while also retaining her Professorial role at the University of Copenhagen.

She says: “NEUmiRNA has an outstanding founder team and is scientifically excellent. The research we are doing addresses major unmet clinical needs and represents a unique opportunity for disease modification rather than symptom management. I am deeply honored to take over the role of CEO from Dr Henrik Klitgaard, who developed the first blockbuster drug for epilepsy.”

For more on Janine Erler’s award-winning career, click here.